Research Chemistry, Novo Nordisk A/S, Novo Nordisk Park H5.S.05, DK-2720 Maaloev, Denmark.
Mol Metab. 2021 Apr;46:101107. doi: 10.1016/j.molmet.2020.101107. Epub 2020 Oct 31.
Hypoglycemia, the condition of low blood sugar, is a common occurance in people with diabetes using insulin therapy. Protecting against hypoglycaemia by engineering an insulin preparation that can auto-adjust its biological activity to fluctuating blood glucose levels has been pursued since the 1970s, but despite numerous publications, no system that works well enough for practical use has reached clinical practise.
This review will summarise and scrutinise known approaches for producing glucose-sensitive insulin therapies. Notably, systems described in patent applications will be extensively covered, which has not been the case for earlier reviews of this area.
The vast majority of published systems are not suitable for product development, but a few glucose-sensitive insulin concepts have recently reached clinical trials, and there is hope that glucose-sensitive insulin will become available to people with diabetes in the near future.
低血糖，即血糖水平低，是接受胰岛素治疗的糖尿病患者的常见病症。自 20 世纪 70 年代以来，人们一直致力于通过工程设计胰岛素制剂，使其能够自动调节生物活性以适应血糖水平的波动，以预防低血糖。但尽管有大量出版物，没有一个系统能够很好地应用于实际，达到临床实践的程度。
这篇综述将总结和审查已知的生产葡萄糖敏感胰岛素疗法的方法。值得注意的是，本综述将广泛涵盖专利申请中描述的系统，这与该领域早期的综述不同。
绝大多数已发表的系统都不适合产品开发，但最近有一些葡萄糖敏感胰岛素的概念已经进入临床试验，人们希望在不久的将来，葡萄糖敏感胰岛素能够供糖尿病患者使用。
